Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial-Reference-Cited by-同舟云学术

Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial

Published:2013-06 Issue:7 Volume:14 Page:599-608
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Jin Jie,Wang Jian-Xiang,Chen Fei-Fei,Wu De-Pei,Hu Jiong,Zhou Jian-Feng,Hu Jian-Da,Wang Jian-Min,Li Jian-Yong,Huang Xiao-Jun,Ma Jun,Ji Chun-Yan,Xu Xiao-Ping,Yu Kang,Ren Han-Yun,Zhou Yu-Hong,Tong Yin,Lou Yin-Jun,Ni Wan-Mao,Tong Hong-Yan,Wang Hua-Feng,Mi Ying-Chang,Du Xin,Chen Bao-An,Shen Yi,Chen Zhu,Chen Sai-Juan

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. Cancer statistics, 2012;Siegel;CA Cancer J Clin,2012

2. Chinese cancer registry annual report;Hao,2012

3. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B;Rai;Blood,1981

4. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia;Br J Haematol,1998

5. Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of minority patients;Pulte;Haematologica,2013

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chromatin as an old and new anticancer target;Trends in Cancer;2024-08

2. Homoharringtonine synergizes with venetoclax in early T cell progenitor acute lymphoblastic leukemia: Bench and bed;Med;2024-08

3. Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia;Journal of Cancer Research and Clinical Oncology;2024-07-06

4. Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing;Cancer Chemotherapy and Pharmacology;2024-07-04

5. Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients;Molecular Cancer;2024-06-04